JLab Hear OTC vs Lexie B3

The JLab Hear OTC is a budget-priced OTC hearing aid released in 2024, earning a B grade with a SoundScore of 3.5/5 in our lab testing. At $100, it represents one of the most affordable entry points into the OTC hearing aid market, ranking #36 of 65 devices in its category. This visible-in-ear device delivers a distinctive performance profile with clear strengths and weaknesses. Its standout feature is excellent music streaming quality, scoring 4.6/5—a remarkable 2.68 points above the category average. Feedback handling is equally impressive at 5.0/5, meaning users can expect stable performance without whistling during daily activities. These results suggest JLab leveraged its audio expertise from consumer earbuds in developing this product. However, speech clarity presents challenges. Speech in quiet scored 2.1/5 (0.67 points below category average), while speech in noise scored 1.0/5 (0.46 points below average). Own-voice comfort also measured low at 1.8/5. These limitations are significant for users prioritizing conversation clarity, which is typically the primary reason people seek hearing aids. The JLab Hear OTC is best suited for budget-conscious consumers who value music and media streaming alongside basic amplification, rather than those needing maximum speech intelligibility. Features include rechargeable batteries, iPhone and Android streaming, and hands-free functionality. Buyers seeking stronger speech performance in this price range may want to compare options like the higher-scoring Elehear Beyond or Apple AirPods Pro 2.

The Lexie B3 is a mid-priced OTC hearing aid available at $999 that achieves an A grade with a SoundScore of 4.7/5 in our lab testing, ranking #1 among 65 OTC hearing aid devices tested. This behind-the-ear style device delivers category-leading performance across multiple metrics. Speech clarity is a standout strength. In our lab testing, the Lexie B3 scores an excellent 4.5/5 for speech in quiet, measuring 1.73 points above the OTC category average. Speech in noise performance scores 2.5/5—above the category average by 1.02 points, though only mixed in absolute terms at 2.5/5. This pattern reflects the broader challenge OTC devices face in noisy environments while still positioning the B3 as a top performer relative to its category. Music streaming quality is solid at 3.3/5, outperforming the category average by 1.38 points. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above average. Feedback handling is excellent at 4.6/5, essentially matching the already-strong category average. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance without prescription hearing aid costs. Those who prioritize speech clarity in quieter settings will find particular value here. Budget-conscious shoppers may want to consider alternatives like the RxEars Rxi, which offers strong performance at a lower price point.